Japanese registry of Rivaroxaban effectiveness & safety for the prevention of recurrence in patients with Deep Vein Thrombosis and Pulmonary Embolism

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary)
Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
Focus Adverse reactions
Acronyms J'xactly Study

30 Mar 2022 Results (n=216) investigating the association between the RV/LV diameter ratio and clinical outcomes in PTE patients under rivaroxaban,published in the International Heart Journal
26 Sep 2020 Results published in the Circulation Journal
15 Sep 2020 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com